Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam

Reuters

2025/12/09

Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam

Lee's Pharmaceutical Holdings Limited is acquiring the Staccato® One Breath Technology® (OBT®) platform and related assets, including global rights as licensor and manufacturer for Staccato® alprazolam, as part of an expanded partnership with UCB. The Staccato® OBT® platform is a proprietary inhalation technology with applications in central nervous system and neurodegenerative disorders, already validated by the approved product Adasuve® and several late-stage development programs. This transaction will also integrate two Phase 2 clinical-stage CNS assets targeting Parkinson's disease and Cyclic Vomiting Syndrome into Lee's Pharm's portfolio. Upon completion, Lee's Pharm and its partner NPI stand to receive up to US$60.5 million in milestone payments, as well as tiered royalties and manufacturing revenue from global sales of Staccato® alprazolam. The transaction is expected to close by the end of 2025, subject to certain conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42284) on December 09, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2590349843"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590349843\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590349843?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 21:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590349843","market":"us","top_or_hot":-1,"title":"Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lee's Pharmaceutical Holdings Limited is acquiring the Staccato® One Breath Technology® (OBT®) platform and related assets, including global rights as licensor and manufacturer for Staccato® alprazolam, as part of an expanded partnership with UCB. The Staccato® OBT® platform is a proprietary inhalation technology with applications in central nervous system and neurodegenerative disorders, already validated by the approved product Adasuve® and several late-stage development programs. This transaction will also integrate two Phase 2 clinical-stage CNS assets targeting Parkinson's disease and Cyclic Vomiting Syndrome into Lee's Pharm's portfolio. Upon completion, Lee's Pharm and its partner NPI stand to receive up to US$60.5 million in milestone payments, as well as tiered royalties and manufacturing revenue from global sales of Staccato® alprazolam. The transaction is expected to close by the end of 2025, subject to certain conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42284) on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-09 21:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lee's Pharmaceutical Holdings Limited is acquiring the Staccato® One Breath Technology® (OBT®) platform and related assets, including global rights as licensor and manufacturer for Staccato® alprazolam, as part of an expanded partnership with UCB. The Staccato® OBT® platform is a proprietary inhalation technology with applications in central nervous system and neurodegenerative disorders, already validated by the approved product Adasuve® and several late-stage development programs. This transaction will also integrate two Phase 2 clinical-stage CNS assets targeting Parkinson's disease and Cyclic Vomiting Syndrome into Lee's Pharm's portfolio. Upon completion, Lee's Pharm and its partner NPI stand to receive up to US$60.5 million in milestone payments, as well as tiered royalties and manufacturing revenue from global sales of Staccato® alprazolam. The transaction is expected to close by the end of 2025, subject to certain conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42284) on December 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL8L61ty:1","article_id":"2590349843","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590349843","pubTimestamp":1765285273,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lee's Pharmaceutical Holdings Limited is acquiring the Staccato One Breath Technology  platform and related assets, including global rights as licensor and manufacturer for Staccato alprazolam, as part of an expanded partnership with UCB. The Staccato OBT platform is a proprietary inhalation technology with applications in central nervous system and neurodegenerative disorders, already validated by the approved product Adasuve and several late-stage development programs. This transaction will also integrate two Phase 2 clinical-stage CNS assets targeting Parkinson's disease and Cyclic Vomiting Syndrome into Lee's Pharm's portfolio. Upon completion, Lee's Pharm and its partner NPI stand to receive up to US$60.5 million in milestone payments, as well as tiered royalties and manufacturing revenue from global sales of Staccato alprazolam. The transaction is expected to close by the end of 2025, subject to certain conditions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","00950":"李氏大药厂"},"translate_title":"李氏制药收购Staccato One Breath技术及阿普唑仑全球权益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00950":0.9},"content_text":"Lee's Pharmaceutical Acquires Staccato One Breath Technology and Global Rights to Alprazolam\n    \n\n        Lee's Pharmaceutical Holdings Limited is acquiring the Staccato® One Breath Technology® (OBT®) platform and related assets, including global rights as licensor and manufacturer for Staccato® alprazolam, as part of an expanded partnership with UCB. The Staccato® OBT® platform is a proprietary inhalation technology with applications in central nervous system and neurodegenerative disorders, already validated by the approved product Adasuve® and several late-stage development programs. This transaction will also integrate two Phase 2 clinical-stage CNS assets targeting Parkinson's disease and Cyclic Vomiting Syndrome into Lee's Pharm's portfolio. Upon completion, Lee's Pharm and its partner NPI stand to receive up to US$60.5 million in milestone payments, as well as tiered royalties and manufacturing revenue from global sales of Staccato® alprazolam. The transaction is expected to close by the end of 2025, subject to certain conditions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lee's Pharmaceutical Holdings Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN42284) on December 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}